Literature DB >> 9168448

Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.

M Blasińska-Morawiec1, T Robak, E Krykowski, A Hellmann, H Urbańska-Ryś.   

Abstract

Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved in only 1 patient, who relapsed after 6 months. Two other patients did not respond to the treatment. HCL-V is a distinct clinicopathological entity which seems to be resistant to various therapeutic modalities. However, further observations are necessary in order to establish the efficacy of 2-CdA in the treatment of HCL-V.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168448     DOI: 10.3109/10428199709114177

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Hairy cell leukemia: clinicopathological and immunophenotypic study.

Authors:  Kaumudi Konkay; Megha S Uppin; Shantveer G Uppin; D Raghunadha Rao; Ch Geetha; T Roshni Paul
Journal:  Indian J Hematol Blood Transfus       Date:  2013-02-06       Impact factor: 0.900

2.  Hairy cell leukemia with unusual loss of CD103 in a subset of the neoplastic population: immunophenotypic and cell cycle analysis by flow cytometry.

Authors:  Constance M Yuan; Li-Jun Yang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 3.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

4.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

5.  Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.

Authors:  Dai Chihara; Evgeny Arons; Maryalice Stetler-Stevenson; Constance Yuan; Hao-Wei Wang; Hong Zhou; Mark Raffeld; Liqiang Xi; Seth M Steinberg; Julie Feurtado; Lacey James-Echenique; Chin-Hsien Tai; Keyur P Patel; Raul C Braylan; Katherine R Calvo; Irina Maric; Alina Dulau-Florea; Robert J Kreitman
Journal:  Blood Adv       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.